BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) granted 16 newly-hired employees stock options to purchase 74,500 shares and restricted stock units covering 51,050 shares. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and have an exercise price of $5.88 per share, vesting in four equal annual installments beginning on the one-year anniversary of the grant date.
12/05/2023 - 04:01 PM
RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 16 newly-hired employees stock options to purchase an aggregate of 74,500 shares, and restricted stock units (RSUs) covering an aggregate of 51,050 shares, of BioCryst common stock. The options and RSUs were granted as of November 30, 2023, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $5.88 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.
About BioCryst Pharmaceuticals ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn .
BCRXW
Contact: jbluth@biocryst.com
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) granted 16 newly-hired employees stock options to purchase 74,500 shares and restricted stock units covering 51,050 shares.
The compensation committee granted 16 newly-hired employees stock options to purchase an aggregate of 74,500 shares.
The options have an exercise price of $5.88 per share, which is equal to the closing price of BioCryst common stock on the grant date.
The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, subject to the new employee’s continued service with the company.
Biocryst Pharmaceuticals Inc.
BCRX Rankings
#4914 Ranked by Stock Gains
BCRX Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Durham
About BCRX
biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
